Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonidegib + buparlisib
- Development stage
- Unknown
- Lead developer
- Adlai Nortye
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Sonidegib + buparlisib** is an investigational oral targeted-therapy combination developed by Novartis. Sonidegib is a small-molecule Smoothened antagonist that suppresses oncogenic Hedgehog signaling, while buparlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor that suppresses PI3K/AKT pathway signaling. The agents were co-administered as separate oral medicines in a Phase 1b dose-escalation and expansion study in advanced solid tumors, including metastatic breast cancer, pancreatic adenocarcinoma, metastatic colorectal cancer, and recurrent glioblastoma, and in a Phase 2 pilot study in advanced or metastatic basal cell carcinoma.
- Other names
- LDE225 + BKM120
02
Targets
PIK3C3 (PI3K class III)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)SMO (Smoothened)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on sonidegib + buparlisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonidegib + buparlisib.